NTLA
Intellia Therapeutics Inc
NASDAQ · Biotechnology
$12.28
+1.19 (+10.73%)
Open$11.32
Previous Close$11.09
Day High$12.33
Day Low$11.32
52W High$28.25
52W Low$5.90
Volume—
Avg Volume6.00M
Market Cap1.42B
P/E Ratio—
EPS$-4.27
SectorBiotechnology
Analyst Ratings
Hold
31 analysts
Price Target
+164.7% upside
Current
$12.28
$12.28
Target
$32.51
$32.51
$20.88
$32.51 avg
$45.64
Key Financials
| FY 2026 | FY 2025 | FY 2025 | |
|---|---|---|---|
| Revenue | 67.82M | 56.27M | 245.97M |
| Net Income | -608,176,655 | -454,126,764 | -43,287,376 |
| Profit Margin | -896.8% | -851.9% | -17.6% |
| EBITDA | -613,991,318 | -483,939,062 | -55,131,039 |
| Free Cash Flow | — | — | -42,116,040 |
| Rev Growth | +20.5% | +20.5% | +17.8% |
| Debt/Equity | — | — | 0.68 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |